Analysis on whether the drug cannot be stopped at will after Tilpotide/Mufenda injection

Tirzepatide is an innovative injectable drug with dual action mechanisms of GLP-1 receptor agonist and GIP receptor agonist. It was initially used to treat type 2 diabetes and has attracted attention in the field of weight management in recent years. It affects insulin secretion, suppresses appetite, and delays gastric emptying through multiple channels, thereby achieving dual effects of blood sugar control and weight loss. However, in actual use, many patients are concerned about whether the drug can be stopped at will, especially after blood sugar or weight has improved.

From the perspective of pharmacological properties, Tilpotide is not a "curative" drug, but relies on long-term effects to maintain its effect. It regulates metabolic status by continuously activating relevant receptors. Once the drug is discontinued, this receptor stimulation will quickly weaken, and the patient's appetite control and insulin sensitivity may gradually return to pre-drug levels. For patients whose main goal is weight loss, sudden discontinuation of medication will often lead to increased caloric intake, decreased basal metabolism, and weight rebound; for patients whose main goal is diabetes management, the risk of blood sugar fluctuations or even increases will also increase.

In addition, during the use of tilpotide, the body will gradually adapt to the drug's effects on metabolism and central satiety signals. Sudden interruption of medication is equivalent to depriving this regulatory mechanism, and the body may have compensatory responses, such as increased hunger, increased food intake, increased glucagon levels, etc., which may undermine the metabolic improvement results achieved. Overseas clinical experience shows that some patients may experience significant weight gain and worsen blood sugar control within a few months after stopping the drug.

Therefore, tilpotide should not be discontinued without medical advice. The correct approach is: when it is necessary to discontinue the drug or adjust the dose, you should communicate with the attending doctor, conduct a comprehensive assessment based on blood sugar, weight, diet and exercise habits, and then gradually reduce the dose or formulate an alternative plan. For some patients who require long-term metabolic management, low-dose long-term medication may be required as part of chronic disease management.

Reference materials:https://www.drugs.com/tirzepatide.html